In Brief
The main aim of the Spirit-HF DZHK08 study is to compare the drug spironolactone to a placebo (a treatment with no medical benefit) in reducing the rate of recurrent hospitalizations and death from heart failure (known as composite endpoints) in people with heart failure (stages classed by the New York Heart Association as II‐IV) with mid‐range or preserved ejection fraction (Left ventricular ejection fraction, LVEF ≥40%).
The SPIRIT-HF-DZHK8 study is 100 percent funded by the German Center for Cardiovascular Research (DZHK).